Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Abstract Background Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation of natural killer (NK) cells. Preclinically, pixatimod inhibits heparan...
Main Authors: | Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0363-5 |
Similar Items
-
The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity
by: Ievgen O. Koliesnik, et al.
Published: (2020-02-01) -
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
by: Criselle D'Souza, et al.
Published: (2021-03-01) -
Immunomodulatory activities of gemifloxacin in mice
by: Muhammad Umair, et al.
Published: (2016-09-01) -
Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes
by: Ida Marie Rundgren, et al.
Published: (2020-01-01) -
The Immunomodulatory Effect of Recombinant Exotoxin A of Pseudomonas Aeruginosa on Dendritic Cells Extracted from Mice Spleen
by: Mohammad Hossein Karimi, et al.
Published: (2015-02-01)